IGF-1 LR3: Common Questions and What the Literature Says

IGF-1 LR3, also written as Long R3 IGF-1 or LR3 IGF-1, is a modified analogue of insulin-like growth factor 1. Search traffic around the compound is dominated by practical questions — particularly whether it has been studied in relation to exercise sessions. This page answers those questions strictly in terms of what the published literature reports, and says plainly where no relevant study exists. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication, or laboratory practice.

The most-searched question: exercise timing

One of the most common searches about this analogue concerns timing relative to a training session. The honest answer from the literature is short: no published, peer-reviewed study has examined IGF-1 LR3 in relation to exercise, resistance training, training schedules, or timing around physical activity. The available primary literature on LR3 IGF-1 comes from fetal sheep physiology, a transgenic mouse model of Alzheimer's disease, and a recombinant protein expression paper. None of those studies involved exercise as a variable, and none involved healthy adult human participants.

That means there is no research basis on which to compare one timing scheme to another, because no study measured any outcome under different timing conditions. Where a question has never been tested, the literature cannot report an answer — and this page does not supply one. Any timing claim circulating online is not traceable to the studies summarised below.

What IGF-1 LR3 is, in the language of the papers

Insulin-like growth factor 1 is an endogenous peptide hormone involved in growth signalling. LR3 IGF-1 is an engineered variant described in the literature as a long-acting analogue: it carries an amino-terminal extension and a substitution at position three, changes intended to reduce binding to IGF binding proteins and extend circulating activity. Researchers use it in experimental settings precisely because it behaves as a longer-acting agonist than native IGF-1.

A 2023 biotechnology paper in Applied Microbiology and Biotechnology illustrates how the analogue enters the research supply chain. The study described recombinant expression of both IGF-1 and LR3 IGF-1 as fusion constructs with xylanase in Pichia pastoris, a yeast expression system, and reported on the production and recovery of the fusion proteins (PMID 37261455). That work concerned manufacturing feasibility rather than any physiological effect in an animal or person, and it is a useful reminder that much of the LR3 IGF-1 literature is laboratory-facing rather than clinical.

The primary animal studies and what they reported

Growth outcomes in fetal sheep

A 2025 study in the American Journal of Physiology — Endocrinology and Metabolism tested whether the analogue would improve growth in late-gestation growth-restricted fetal sheep. The title states the result directly: IGF-1 LR3 did not promote growth in that model (PMID 39679943). The study is notable because it tested a growth hypothesis in a setting where growth was impaired, and the researchers reported a negative result rather than a benefit.

This matters for how the compound is discussed publicly. Because IGF-1 signalling is associated with growth, it is often assumed that an extended-action analogue must produce growth effects in any tissue or context. The fetal sheep work is a direct example of the literature reporting no growth promotion in a specific model. It does not generalise to adult skeletal muscle, and the study did not examine that tissue or that population.

Insulin secretion and glucose handling

A 2023 paper in the Journal of Developmental Origins of Health and Disease examined glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep. Researchers reported that insulin secretion in response to glucose was attenuated during the infusion, but that the attenuation did not persist when islets were isolated and studied outside the animal (PMID 37114757). The distinction the study drew — an in vivo effect that was absent at the isolated-islet level — suggests the response observed was systemic rather than an intrinsic change in the islet itself.

The metabolic overlap between IGF-1 and insulin signalling is the reason glucose handling appears repeatedly in this literature. The study above is one of the few primary reports describing a measured metabolic consequence of LR3 IGF-1 administration in a living animal, and it was conducted in fetal physiology, not adult metabolism.

Central nervous system model

A 2025 study in the Journal of Alzheimer's Disease delivered long R3 IGF-1 intranasally to male 5XFAD mice, a transgenic amyloid model. Researchers reported that the treatment promoted amyloid plaque remodeling in the cerebral cortex but failed to preserve cognitive function (PMID 39610283). The study is a clear illustration of a dissociation between a biomarker-level change and a functional outcome: the pathology measure moved, the behavioural measure did not follow.

Readers looking for cognitive or neuroprotective claims about this analogue should note that the outcome reported was a failure to preserve cognitive function in that model. The study also used an intranasal route in mice, which does not map onto any other route or species.

Adverse Events and Metabolic Signals in Animal Studies: What Studies Report

There is no published safety trial of IGF-1 LR3 in humans, so there is no human adverse-event dataset to summarise. What the verified literature does contain are physiological observations from animal infusions:

• Reduced glucose-stimulated insulin secretion during acute infusion. The fetal sheep study reported attenuated insulin secretion in response to glucose while the analogue was infused, with the effect not persisting in isolated islets (PMID 37114757).
• No growth benefit where growth was the target. In growth-restricted late-gestation fetal sheep, the analogue did not promote growth (PMID 39679943). A null result is not an adverse event, but it is relevant to expectations.
• Biomarker change without functional benefit. In the Alzheimer's mouse model, cortical plaque remodeling occurred while cognitive function was not preserved (PMID 39610283).

Broader concerns often raised about IGF-1 pathway agonists — such as hypoglycaemia risk or proliferative signalling — are not addressed by the four verified studies above, and this page does not assign numbers or probabilities to risks the cited papers did not measure.

Questions the literature does not answer

Stating absence clearly is part of an honest evidence summary. As of the verified papers reviewed here, no published study has reported on:

1. Timing of administration relative to exercise sessions or training blocks.
2. Muscle mass, strength, hypertrophy, or body-composition outcomes in humans.
3. Comparative outcomes between LR3 IGF-1 and native IGF-1 in adult humans.
4. Long-term safety, tumour surveillance, or endocrine follow-up in any human cohort.
5. Combination with any other peptide, hormone, or pharmaceutical agent.
6. Injection site, route comparison, or administration frequency in humans.

Because none of these were studied, no conclusion about them can be attributed to the literature. Content that presents such conclusions is extrapolating beyond the published record.

How to interpret the small evidence base

Three features of the LR3 IGF-1 literature shape what can reasonably be said about it.

The models are specialised

Fetal sheep physiology and transgenic amyloid mice are chosen for mechanistic precision, not because they resemble healthy adults. An effect reported in a late-gestation fetus, whose growth and metabolic regulation differ fundamentally from an adult's, cannot be translated to adult tissue (PMID 39679943).

Routes differ

The verified studies used intravascular infusion in sheep and intranasal delivery in mice (PMID 39610283). Route affects exposure, distribution, and which tissues see the compound, so findings do not transfer across routes.

Negative and dissociated results are common

Two of the four verified papers reported outcomes that fell short of the hypothesis being tested — no growth promotion in one, no cognitive preservation in the other. In a literature this small, those results carry proportionally more weight than they would in a large field.

Regulatory context

IGF-1 LR3 is not an approved medicine. Material of this kind is typically labelled for research use only, which means it is intended for laboratory investigation and is not supplied or characterised for human administration. The 2023 expression paper describes the analogue in exactly that frame — as a recombinant protein produced in a yeast system for research and production purposes (PMID 37261455). Research-use material is not subject to the identity, purity, and sterility requirements that apply to approved injectable drug products.

Bottom line from the published record

The searched question about exercise timing has no published answer, because no study has tested it. What the literature does contain is a narrow set of animal and laboratory reports: no growth promotion in growth-restricted fetal sheep (PMID 39679943), attenuated glucose-stimulated insulin secretion during acute infusion that did not persist in isolated islets (PMID 37114757), amyloid plaque remodeling without preserved cognition in a mouse model (PMID 39610283), and recombinant production work in yeast (PMID 37261455). Anyone weighing claims about this compound can use that list as a baseline for what the evidence actually supports.

References

• IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep (American Journal of Physiology. Endocrinology and Metabolism, 2025)
• Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice (Journal of Alzheimer's Disease, 2025)
• Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets (Journal of Developmental Origins of Health and Disease, 2023)
• Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris (Applied Microbiology and Biotechnology, 2023)